Glucosamine, a popular joint supplement, linked to faster Alzheimer’s progression

A U.S. study cited by UA.NEWS links glucosamine use to the advancement of cognitive impairment, while the European Medical Journal questions whether the supplement also raises mortality risk. ScienceAlert quantifies the association as a 25 percent increase in dementia risk for people with early memory decline. The story quickly spread across health and science outlets. The European Medical Journal published a peer‑reviewed analysis titled “Does Glucosamine Accelerate Dementia and Mortality Risk?”; ScienceAlert ran a headline‑style piece on the 25 percent risk figure; Yahoo Health highlighted an “unexpected risk in older adults.” Firstpost gathered comments from physicians about potential brain effects, and Northeastern Global News placed glucosamine among three trusted supplements now under scrutiny.

Korean business daily 매일경제 warned that the findings could turn “a warning light on” for parents using the product for joint pain. Glucosamine has been marketed for decades as a safe, over‑the‑counter remedy for osteoarthritis, with sales driven by an aging population seeking joint relief. Its widespread availability and perception of low risk have led to routine daily use by millions worldwide. The new research challenges that perception by suggesting a link between the supplement’s biochemical pathways and amyloid or tau processes implicated in Alzheimer’s, raising questions about long‑term safety for a demographic already vulnerable to cognitive decline.

Future coverage will likely track follow‑up studies that aim to replicate or refute the initial findings, as well as any statements from regulatory agencies such as the FDA or European Medicines Agency. Watch for guidance from professional societies on supplement recommendations for seniors, and for potential updates from manufacturers regarding label warnings. The evolving evidence base will determine whether glucosamine remains a mainstream joint aid or is reclassified as a risk factor for neurodegenerative disease.